ライフサイエンスコーパス: tularemia

1 e damage that characterizes lethal pneumonic tularemia.

2 the wild type in a mouse model of pneumonic tularemia.

3 virulent in the murine model of subcutaneous tularemia.

4 ely reduced in the murine model of pneumonic tularemia.

5 for virulence in a mouse pulmonary model of tularemia.

6 embryos and in the murine model of pneumonic tularemia.

7 and is the etiological agent of the disease tularemia.

8 ns in intranasal inoculation mouse models of tularemia.

9 ncisella tularensis causes the human disease tularemia.

10 the role of type I IFNs in a mouse model of tularemia.

11 e highly infectious animal and human disease tularemia.

12 ancisella tularensis, the causative agent of tularemia.

13 vaccines and therapeutics against pneumonic tularemia.

14 sed clinically to improve treatments against tularemia.

15 uses a lethal infection that resembles human tularemia.

16 e attributes in a mouse model of respiratory tularemia.

17 macrophages and a mouse model of respiratory tularemia.

18 ellular bacterium, is the etiologic agent of tularemia.

19 is a highly infectious pathogen that causes tularemia.

20 cellular pathogen and the causative agent of tularemia.

21 of cell types and is the causative agent of tularemia.

22 r smallpox and botulism than for anthrax and tularemia.

23 cellular pathogen and the causative agent of tularemia.

24 ellular bacterium, is the causative agent of tularemia.

25 sis infects wild animals and humans to cause tularemia.

26 ium that is the causative agent of pulmonary tularemia.

27 lls following inhalation in a mouse model of tularemia.

28 ses the potentially life-threatening disease tularemia.

29 the causative agent of the zoonotic disease tularemia.

30 cellular pathogen and the etiologic agent of tularemia.

31 racellular pathogen that causes the zoonosis tularemia.

32 resistance to F. novicida-induced pneumonic tularemia.

33 leading to protective immunity to pneumonic tularemia.

34 ver and spleen in a mouse model of pulmonary tularemia.

35 ys a role in the pathogenesis of respiratory tularemia.

36 at the IL-23 response may be relevant during tularemia.

37 tants may be useful for immunization against tularemia.

38 ive coccobacillus, is the causative agent of tularemia.

39 ancisella tularensis, the causative agent of tularemia.

40 fectious pathogen and the causative agent of tularemia.

41 ellular bacterium, is the etiologic agent of tularemia.

42 be of use in the design of a vaccine against tularemia.

43 sella tularensis causes the zoonotic disease tularemia.

44 in tempering the host response to pneumonic tularemia.

45 ensis causes a lethal human disease known as tularemia.

46 lar pathogen and is the etiological agent of tularemia.

47 cisella tularensis is the causative agent of tularemia.

48 ative coccobacillus that causes the zoonosis tularemia.

49 tive immunity in protection from respiratory tularemia.

50 agents potentially efficacious for treating tularemia.

51 Mice were infected to produce respiratory tularemia.

52 ring requires special media and suspicion of tularemia.

53 the causative agent of the zoonotic disease tularemia.

54 identify risk factors for primary pneumonic tularemia.

55 None of them developed signs or symptoms of tularemia.

56 the laboratory of the clinical suspicion of tularemia.

57 2000, and had a positive laboratory test for tularemia.

58 ia; 11 of these cases were primary pneumonic tularemia.

59 d nonbacteremic and 10 had bacteremic severe tularemia.

60 rms were available for 1163 US patients with tularemia.

61 t causes a potentially lethal disease called tularemia.

62 oquinolone treatment is effective for severe tularemia.

63 hed for articles containing terms related to tularemia.

64 nes are an effective option for treatment of tularemia.

65 fy the cynomolgus macaque model of pneumonic tularemia.

66 e findings suggest the potential for chronic tularemia.

67 nd outcomes for this rare but severe form of tularemia.

68 upational exposure to animals with confirmed tularemia.

69 nonbacteremic and 115.0 hours in bacteremic tularemia.

70 confirmed F. tularensis infection to prevent tularemia.

71 laboratory, and treatment outcomes of type B tularemia.

72 m that causes an acute, fatal disease called tularemia.

73 cisella tularensis is the causative agent of tularemia.

74 ship to Francisella tularensis, the agent of tularemia.

75 egative bacterium, is the causative agent of tularemia.

76 s contracted laboratory-verified respiratory tularemia.

77 nfection and virulence in the mouse model of tularemia.

78 m that causes the potentially lethal disease tularemia.

79 negative pathogen and the causative agent of tularemia.

80 therapeutic benefits for protection against tularemia.

81 cellular pathogen and the causative agent of tularemia.

82 erium and the causative agent of the disease tularemia.

83 acterial pathogen and the causative agent of tularemia.

84 bacterium that causes the zoonotic infection tularemia.

85 ve agent of the debilitating febrile illness tularemia.

86 rtant human pathogen responsible for causing tularemia.

87 ese cells in the protective host response to tularemia.

88 ophages and are avirulent in mouse models of tularemia.

89 ghly virulent in humans, causing the disease tularemia.

90 cellular pathogen and the causative agent of tularemia.

91 ar pathogen that causes the zoonotic disease tularemia.

92 n of this organism as a vaccine platform for tularemia.

93 and is the etiological agent of the disease tularemia.

94 ctive during infection in the mouse model of tularemia.

95 dependent differences in the pathogenesis of tularemia.

96 ntibody Ab52 in a mouse model of respiratory tularemia.

97 ent bacteria that cause the zoonotic disease tularemia.

98 We identified 15 patients with tularemia; 11 of these cases were primary pneumonic tula

99 Mass., has been the site of two outbreaks of tularemia (1978 and 2000).

100 s of 121 of 190 patients (64%) reported with tularemia; 79 (65%) were males; the median age was 37 ye

101 cisella tularensis is the causative agent of tularemia, a category A bioterrorism agent.

102 y grow within mammalian hosts, often causing tularemia, a fatal disease.

103 cular weight (HMW)], and in a mouse model of tularemia, a glycoconjugate vaccine made with the HMW po

104 Francisella tularensis causes tularemia, a highly contagious disease of animals and hu

105 cisella tularensis is the etiologic agent of tularemia, a potentially fatal disease if untreated.

106 Tularemia, a potentially fatal zoonosis caused by Franci

107 ularensis is the causative agent of zoonotic tularemia, a severe pneumonia in humans, and Francisella

108 n ophthalmological manifestations related to tularemia, a zoonose caused by the bacterium Francisella

109 cisella tularensis is the causative agent of tularemia, a zoonosis that can affect humans with potent

110 erial pathogen Francisella tularensis causes tularemia, a zoonosis that can be fatal.

111 Lyme disease spirochetes and rickettsial or tularemia agents as models for extracellular and intrace

112 s currently available for protection against tularemia, although an attenuated strain, dubbed the liv

113 n were efficacious in treatment of pneumonic tularemia, although clearance of bacteria may be differe

114 cisella tularensis is the causative agent of tularemia and a category A potential agent of bioterrori

115 ive bacterium that is the causative agent of tularemia and a potential bioweapon.

116 e nearest neighbor to the causative agent of tularemia and category A select agent Francisella tulare

117 l features may prompt clinicians to consider tularemia and facilitate appropriate testing.

118 and consideration as potential vaccines for tularemia and for identification of immunological correl

119 subsp. tularensis is the etiologic agent of tularemia and has been designated a category A biothreat

120 egative bacterium, is the etiologic agent of tularemia and has recently been classified as a category

121 clinical course and severity of respiratory tularemia and identifies MMPs as novel targets for thera

122 case-control study of adults with pneumonic tularemia and investigated the environment to identify r

123 cisella tularensis is the causative agent of tularemia and is a category A select agent.

124 cisella tularensis is the causative agent of tularemia and is classified as a category A biodefense a

125 al pathogen that causes the zoonotic disease tularemia and is important to biodefense.

126 s yield new insight into the pathogenesis of tularemia and may have important ramifications in the se

127 en handling sick animals to minimize risk of tularemia and other zoonotic infections; postexposure pr

128 earch tools to explore the roles of Flpp3 in tularemia and should enable the development of new thera

129 of utilizing a live vaccine strategy against tularemia and the necessity for identifying novel, acell

130 ular gram-negative coccobacillus that causes tularemia, and its virulence and infectiousness make it

131 such as Q fever, rickettsioses, brucelloses, tularemia, and other bartonelloses.

132 ority bioterror concerns, including anthrax, tularemia, and plague, are caused by bacteria that acute

133 causing, for example, tuberculosis, malaria, tularemia, and plague.

134 linical features classically associated with tularemia are absent.

135 atment, and illness outcome of patients with tularemia are provided voluntarily through case report f

136 uggest that natural outbreaks of respiratory tularemia are triggered by environmental cues.

137 Other manifestations of tularemia are very rare, especially those with musculosk

138 cisella tularensis biovar A causes pneumonic tularemia associated with high morbidity and mortality r

139 e hundred seventy humans were diagnosed with tularemia between 1981 and 2007, 94% of them during 7 su

140 ting attacks with anthrax, smallpox, plague, tularemia, botulism, or hemorrhagic fever viruses.

141 oroquinolones lack approval for treatment of tularemia but have been used extensively for milder illn

142 Diagnosis of tularemia by blood culture and nucleic acid-based diagno

143 lization for >24 hours and severe bacteremic tularemia by Francisella tularensis subsp.

144 We defined severe tularemia by hospitalization for >24 hours and severe ba

145 fectious intracellular bacterium that causes tularemia by invading and replicating in mammalian myelo

146 cks and tested them in pools for evidence of tularemia by PCR.

147 or infection in a mouse model of respiratory tularemia by signature-tagged mutagenesis.

148 attenuated for virulence in a mouse model of tularemia by the intradermal route.

149 re not notified of the clinical suspicion of tularemia by the service caring for the patient.

150 To characterize cell death in tularemia, C57BL/6 mice were challenged by the intranasa

151 Data from reported tularemia cases (aged >10 years at time of study) in Nor

152 l protein) discriminated between the Spanish tularemia cases and healthy controls.

153 the Schu S4 array with sera from 241 type B tularemia cases in Spain.

154 filed the antibody responses in type A and B tularemia cases in the United States using a proteome mi

155 d treatment outcomes of laboratory-confirmed tularemia cases over an 11-year period in Northern Swede

156 Tularemia caused by Francisella tularensis is a zoonotic

157 ould also have utility for diagnosing type B tularemia caused by strains from other geographic locati

158 Inhalational pneumonic tularemia, caused by Francisella tularensis, is lethal i

159 Outbreaks of respiratory tularemia, caused by inhalation of this bacterium, are p

160 Articles with case-level data on tularemia diagnosis, antimicrobial treatment, and patien

161 Although rare, tularemia during pregnancy has been associated with preg

162 plications have been reported among cases of tularemia during pregnancy.

163 tance of prompt recognition and treatment of tularemia during pregnancy.

164 ella tularensis (Ft), the causative agent of tularemia, elicits a potent inflammatory response early

165 prerequisite for outbreaks of tularemia in a tularemia-endemic boreal forest area of Sweden and that

166 y which Francisella tularensis, the agent of tularemia, enters host macrophages.

167 glandular (37%) and glandular (25%) forms of tularemia, followed by pneumonic (12%), typhoidal (10%),

168 we identified case-patients with respiratory tularemia from July to November 2010 in Jamtland County,

169 Tularemia has a range of recognized clinical manifestati

170 e development of a vaccine against pneumonic tularemia has been limited by a lack of information rega

171 early hepatic lesions of experimental murine tularemia has not been characterized with specific marke

172 ich is a Gram negative bacterium that causes tularemia, has been classified by the Center for Disease

173 ancisella tularensis, the causative agent of tularemia, has been designated a CDC category A select a

174 tive agent of a fatal human disease known as tularemia, has been used in the bioweapon programs of se

175 , fluoroquinolones are used for treatment of tularemia; however, data on the relative effectiveness o

176 ccine currently available to protect against tularemia; however, this unlicensed vaccine is relativel

177 Study of this outbreak of primary pneumonic tularemia implicates lawn mowing and brush cutting as ri

178 A rapidly fatal case of pulmonary tularemia in a 43-year-old man who was transferred to a

179 that these can be used for the diagnosis of tularemia in a deployable format, such as the immunostri

180 te summer is a prerequisite for outbreaks of tularemia in a tularemia-endemic boreal forest area of S

181 Here, we report on a human case of tularemia in a veterinarian after an accidental needlest

182 hould lead to early suspicion of intentional tularemia in an alert health system; laboratory confirma

183 tion of Bacillus anthracis, botulinum B, and tularemia in complex matrices.

184 predict annual numbers of humans contracting tularemia in Dalarna County, Sweden.

185 tential vaccine candidates against pneumonic tularemia in experimental animals.

186 now report the natural history of pneumonic tularemia in female Fischer 344 rats after nose-only inh

187 rensis is the bacterial pathogen that causes tularemia in humans and a number of animals.

188 Tularemia in humans is caused mainly by two subspecies o

189 Although primary pneumonic tularemia in humans typically occurs by inhalation of ae

190 n of Francisella tularensis causes pneumonic tularemia in humans, a severe disease with a 30 to 60% m

191 ancisella tularensis, the etiologic agent of tularemia in humans, is a potential biological threat du

192 ancisella novicida causes a similarly severe tularemia in mice upon inhalation.

193 To define the epidemiology of tularemia in Missouri, and to evaluate practices and out

194 biovar A, possibly reflecting the history of tularemia in North America.

195 entified, 30 articles describing 52 cases of tularemia in pregnant patients met inclusion criteria.

196 udies because it causes a disease similar to tularemia in rodents but is not harmful to humans.

197 A localized outbreak of tularemia in Sweden was investigated.

198 Overall, the pathogenesis of pneumonic tularemia in the female F344 rat model appears to replic

199 mortality or recovery following induction of tularemia in the mouse will improve our understanding of

200 ly previously reported outbreak of pneumonic tularemia in the United States also occurred on the isla

201 ancisella tularensis, the causative agent of tularemia, in which pathways triggered by IFN-gamma comm

202 veitis may be an infrequent manifestation of tularemia infection, and therefore this infection should

203 rt a case of intraocular inflammation during tularemia infection.

204 ancisella tularensis, the causative agent of tularemia, infects host macrophages, which triggers prod

205 ancisella tularensis, the bacterial cause of tularemia, infects the liver and replicates in hepatocyt

206 ancisella tularensis, the causative agent of tularemia, interacts with host cells of innate immunity

207 Tularemia is a deadly, febrile disease caused by infecti

208 Tularemia is a debilitating febrile illness caused by th

209 Tularemia is a disease caused by Francisella tularensis,

210 Tularemia is a highly infectious zoonotic disease caused

211 Pneumonic tularemia is a life-threatening disease caused by inhala

212 Tularemia is a potentially fatal disease that is caused

213 y vaccine known to confer protection against tularemia is a specific live vaccine strain (designated

214 Tularemia is a zoonosis of humans caused by infection wi

215 Tularemia is an important reemerging disease with a mult

216 The current serological test for tularemia is based on agglutination of whole organisms,

217 Pneumonic tularemia is caused by inhalation of Francisella tularen

218 Tularemia is caused by the category A biodefense agent F

219 Tularemia is caused by the Gram-negative bacterial patho

220 Tularemia is caused by the gram-negative bacterium Franc

221 Tularemia is caused by the highly infectious bacterium F

222 Tularemia is characterized by replication and disseminat

223 Tularemia is considered as a life-threatening potential

224 Clinical recognition of tularemia is essential for prompt initiation of appropri

225 Tularemia is frequently initially misdiagnosed.

226 s of various antimicrobials for treatment of tularemia is limited, particularly for newer classes suc

227 tential for illicit use, the pathogenesis of tularemia is not well understood.

228 Tularemia is the zoonotic disease caused by the gram-neg

229 Tularemia is treatable with antibiotics; however, there

230 y medical and public health professionals if tularemia is used as a biological weapon against a civil

231 The incidence of pneumonic tularemia is very low; therefore, it is not feasible to

232 ancisella tularensis, the causative agent of tularemia, is a category A bioterrorism agent.

233 ancisella tularensis, the causative agent of tularemia, is a highly virulent microbe.

234 nsis, the highly virulent etiologic agent of tularemia, is a low-dose intracellular pathogen that is

235 ancisella tularensis, the causative agent of tularemia, is a pathogenic bacterium that replicates in

236 Francisella tularensis, the agent of tularemia, is an intracellular pathogen, but little is k

237 cisella tularensis, the etiological agent of tularemia, is capable of infecting a wide range of anima

238 ultative intracellular bacterium that causes tularemia, is considered a biothreat because of its high

239 ancisella tularensis, the causative agent of tularemia, is endemic throughout the Northern Hemisphere

240 cisella tularensis, the etiological agent of tularemia, is found throughout the Northern hemisphere.

241 racellular bacterium responsible for causing tularemia, is highly pathogenic and classified as a cate

242 ancisella tularensis, the causative agent of tularemia, is in the top category (category A) of potent

243 ancisella tularensis, the causative agent of tularemia, is most deadly in the pneumonic form; therefo

244 ancisella tularensis, the causative agent of tularemia, is one of the deadliest agents of biological

245 cisella tularensis, the etiological agent of tularemia, is one of the most infectious bacteria known.

246 ancisella tularensis, the causative agent of tularemia, is one of the most infectious bacterial patho

247 ancisella tularensis, the causative agent of tularemia, is phagocytosed by immune cells such as monoc

248 ancisella tularensis, the causative agent of tularemia, is rare.

249 he pathological characteristics of pulmonary tularemia leading to systemic disease, and potentially i

250 arensis novicida, a subspecies that causes a tularemia-like disease in rodents.

251 i, and to evaluate practices and outcomes of tularemia management in general, we conducted a detailed

252 ible to conduct clinical efficacy testing of tularemia medical countermeasures (MCMs) in humans.

253 ancisella tularensis, the causative agent of tularemia, modulates the host immune response to gain a

254 5.7%), there were several cases of pulmonary tularemia (n = 40; 12.2%).

255 ancisella tularensis, the bacterial agent of tularemia, occur infrequently in humans.

256 er of 2000, an outbreak of primary pneumonic tularemia occurred on Martha's Vineyard, Massachusetts.

257 diated protection against lethal respiratory tularemia occurs after mucosal vaccination with inactiva

258 omorbidity index predicted severe bacteremic tularemia (odds ratio, 2.7 per score-point; 95% confiden

259 The diagnosis of human cases of tularemia often relies upon the demonstration of an anti

260 been long-standing enzootic transmission of tularemia on the island.

261 ents with meningitis and signs suggestive of tularemia or compatible exposures, lymphocyte-predominan

262 s could potentially help in the treatment of tularemia or even be utilized to neutralize the infectio

263 sella tularensis is the etiological agent of tularemia, or rabbit fever.

264 The factors that precipitated the tularemia outbreaks or the proximal determinants of huma

265 associate responsiveness to polyamines with tularemia pathogenesis and define FTL_0883/FTT_0615c as

266 in vitro-derived findings may be relevant to tularemia pathogenesis in the mammalian host.

267 hages and neutrophils play distinct roles in tularemia pathogenesis, such that macrophages are major

268 ct bacterial dissemination after respiratory tularemia, provide new insights regarding the pathologic

269 Most US patients with tularemia received high-efficacy antimicrobials; their u

270 re effective antimicrobials for treatment of tularemia, regardless of clinical manifestation.

271 Targeting tularemia requires clinical awareness, early diagnosis,

272 The veterinarian developed ulceroglandular tularemia requiring hospitalization but fully recovered

273 ical investigations and characterizations of tularemia source outbreaks.

274 ons during epidemiological investigations of tularemia source outbreaks.

275 ancisella tularensis, the causative agent of tularemia, survives and proliferates within macrophages

276 ntly preceded the median onset time of human tularemia (temporal correlation, 0.76; P < .05).

277 attenuation of virulence in a mouse model of tularemia that could be complemented by addition of tolC

278 In a mouse model of tularemia, the DeltafupA mutant was attenuated, but the

279 livered intranasally can prevent respiratory tularemia through a mechanism that is at least partially

280 a with transmission of the bacterial disease tularemia to humans, and model the annual variation of d

281 were obtained in a mouse model of pneumonic tularemia using the highly virulent F. tularensis subspe

282 ta suggest that improved efficacy of current tularemia vaccine platforms will require targeting appro

283 The frequency for tularemia was 6.91%.

284 Among 16 published cases, tularemia was clinically suspected in 4 cases.

285 ther infectious and non-infectious etiology, tularemia was diagnosed by advanced serology consisting

286 Tularemia was often misdiagnosed on presentation (n = 15

287 ther patient presented with meningeal signs; tularemia was suspected based on animal exposure, and F.

288 Although ulceroglandular tularemia was the predominant form (n = 215, 65.7%), the

289 fort to develop a rapid diagnostic assay for tularemia, we investigated the use of TaqMan 5' hydrolys

290 In the murine model of pulmonary type A tularemia, we showed the presence of intraerythrocytic b

291 The splenic Gr-1(+) CD11b(+) cells in tularemia were a heterogeneous population that could be

292 tries, and oropharyngeal and ulceroglandular tularemia were the most common presenting forms.

293 had symptoms suggestive of primary pneumonic tularemia, were ill between May 15 and October 31, 2000,

294 erring protection against lethal respiratory tularemia when given 24-48 h postexposure.

295 associated with protection from respiratory tularemia, whereas a deregulated host response leading t

296 causes lethal infection that resembles human tularemia, whereas the LD50 for an intradermal infection

297 igate cell-mediated immune responses against tularemia, whose sporadic incidence makes clinical trial

298 Articles reporting cases of tularemia with >=1 maternal or fetal outcome were includ

299 izes what is known about the pathogenesis of tularemia with a focus on bacterial surface components s

300 A weapon using airborne tularemia would likely result 3 to 5 days later in an ou

301 ause this strain was attenuated in pneumonic tularemia yet induced a protective immune response.